Citations

Clear

941 citation(s) found for "Tan, B".

Objective but Not Subjective Short Sleep Duration Is Associated With Hypertension in Obstructive Sleep Apnea
Ren, Rong , Covassin, Naima , Yang, Linghui , Zhang, Ye , Zhou, Junying , Tan, Lu, Li, Taomei , Li, Xiao , Wang, Yanyan , Zhang, Jihui , Tang, Xiangdong , Tang, Xiangdong , Li, Yun , Tan, Lu, Wing, Yun Kwok , Li, Weimin , Somers, Virend K.

Mayo Clinic

Hypertension | July 9, 2018 | Volume: 72 | Issue: 3 | Pages: 610-617

10.1161/hypertensionaha.118.11027 | PMID 29987105 Get It

Extremes of sleep duration and obstructive sleep apnea (OSA) are both associated with hypertension. We aimed to explore whether sleep duration modifies the relationship between OSA and prevalent hypertension, using both objective and subjective measures of total sleep duration. A total of 7107 OSA patients and 1118 primary snorers were included in the study. Hypertension was defined based either on direct blood pressure measures or on diagnosis by a physician. Objective sleep duration was derived by polysomnography and subjective sleep duration was self-reported. Logistic regression models were used to estimate the associations between objective/subjective sleep duration and hypertension prevalence in OSA and primary snorers. Compared with primary snorers, OSA combined with objective sleep duration of 5 to 6 hours increased the odds of hypertension by 45% (odds ratio, 1.45; 95% confidence interval, 1.14–1.84), whereas OSA combined with objective sleep duration <5 hours further increased the odds of hypertension by 80% (odds ratio, 1.80; 95% confidence interval, 1.33–2.42). These results were independent of major confounding factors frequently associated with OSA or hypertension. In stratified analysis by sleep duration, risk of hypertension in those with extremely short sleep (<5 hours) was not significantly different between OSA and primary snorers, whereas odds were significant for OSA in the other 4 sleep duration strata (5–6, 6–7, 7–8, and >8 hours). No significance was evident using subjective sleep duration. We conclude that objective short sleep duration is associated with hypertension in OSA patients. Extremely short sleep duration in itself may actually be even more detrimental than OSA in terms of hypertension risk.
Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients
Hu, Rou-Mu, Tester, David J. , Li, Ryan , Sun, Tianyu , Peterson, Blaise Z., Ackerman, Michael J. , Makielski, Jonathan C., Tan, Bi-Hua, Li, Ryan, Tan, Bi‐Hua

Mayo Clinic

Channels | July 7, 2018 | Volume: 12 | Issue: 1 | Pages: 176-186

10.1080/19336950.2018.1475794 | PMID 29983085 Get It

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study
Qian, Frank , Wang, Shengfeng , McGuffog, Lesley, Barrowdale, Daniel , Oosterwijk, Jan C., Evans, D. Gareth , Engel, Christoph , Kast, Karin, Aalfs, Cora M. , Adank, Muriel A. , Agnarsson, Bjarni A. , Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L. , Ausems, Margreet G.E.M. , Azzollini, Jacopo , Barouk-Simonet, Emmanuelle, Belotti, Muriel, Benı́tez, Javier , Berger, Andreas, Borg, Åke , Bradbury, Angela R. , Brunet, Joan , Caldés, Trinidad , Caputo, Sandrine M. , Chiquette, Jocelyne , Collée, J. Margriet, Coupier, Isabelle, Daly, Mary B., Davidson, Rosemarie, Donaldson, Alan, Dorfling, Cecilia M., Eeles, Rosalind A. , Feliubadaló, Lídia , Foretová, Lenka , Fowler, Jeffrey M., Friedman, Eitan , Frost, Debra, Ganz, Patricia A. , García‐Barberán, Vanesa , Glendon, Gord , Gómez, E. , Hahnen, Eric , Hamann, Ute, Henderson, Alex, Hendricks, Carolyn B., Hulick, Peter J. , Imyanitov, Evgeny N., Izatt, Louise , Jakubowska, Anna , Kaczmarek, Katarzyna, Kang, Eunyoung , Kets, Carolien M., Kim, Sung-Won, Kwong, Ava , Laitman, Yael , Lasset, Christine, Lee, Min Hyuk , Lee, Jong Won, Lee, Jihyoun , Lester, Jenny, Lesueur, Fabienne , Loud, Jennifer T. , Mebirouk, Noura, Meijers‐Heijboer, Hanne , Meindl, Alfons , Montagna, Marco , Mooij, Thea M. , Mouret‐Fourme, Emmanuelle, Nathanson, Katherine L. , Niederacher, Dieter , Offit, Kenneth, Oláh, Edith , Ong, Kai-Ren, Ottini, Laura , Park, Sue K. , Peterlongo, Paolo , Pfeiler, Georg , Phelan, Catherine M., Poppe, Bruce , Pradhan, Nisha , Radice, Paolo , Ramus, Susan J. , Rantala, Johanna, Rodriguez, Gustavo C. , Schmutzler, Rita K., Selkirk, Christina G. , Shah, Payal D. , Simard, Jacques , Sutter, Christian , Tan, Yen Y. , Teixeira, R , Teo, Soo‐Hwang , Terry, Mary Beth , Thomassen, Mads , Toland, Amanda Ewart, Tucker, Kathy , Engelen, Klaartje van , Rensburg, Elizabeth J. van , Wang‐Gohrke, Shan , Wappenschmidt, Barbara , Weitzel, Jeffrey N. , Collaborators, GEMO Study, HEBON, EMBRACE, Greene, Mark H. , Rookus, Matti A. , Easton, Douglas F. , Chenevix‐Trench, Georgia , Antoniou, Antonis C. , Goldgar, David E., Olopade, Olufunmilayo I. , Huo, Dezheng , Durocher, Francine , Teixeira, Manuel R. , Mitchell, Jonathan A. , Białkowska, Katarzyna , Hulick, Peter J , Lesueur, Fabienne , Peterlongo, Paolo , Ramus, Susan J , Teixeira, Manuel R , Teo, Soo H , van Rensburg, Elizabeth J , Radice, Paolo , Weitzel, Jeffrey N , Azzollini, Jacopo , Brunet, Joan , Eeles, Rosalind A , Evans, D Gareth , Olopade, Olufunmilayo I , Jakubowska, Anna , Nathanson, Katherine L , Barrowdale, Daniel , Benitez, Javier , Engel, Christoph , Montagna, Marco , Simard, Jacques , Chenevix-Trench, Georgia , Ottini, Laura , Mitchell, Jonathan S. , Leslie, Goska , Chung, Wendy K. , Adlard, Julian , Arun, Banu , Barwell, Julian , Borg, Åke , Buys, Saundra S. , Caligo, Maria A. , Campbell, Ian , Claes, Kathleen , Couch, Fergus J. , Dı́ez, Orland , Domchek, Susan M. , Garber, Judy E. , Godwin, Andrew K. , Gronwald, Jacek , Hopper, John L. , Isaacs, Claudine , Izquierdo, Á. , Karlan, Beth Y. , Kim, Sung-Won , Lasset, Christine , Lubiński, Jan , Meindl, Alfons , Miller, Austin , Morrison, Patrick J. , Neuhausen, Susan L. , Nevanlinna, Heli , Nielsen, Finn Cilius , Nussbaum, Robert L. , Robson, Mark E. , Singer, Christian F. , Giles, Graham G , Stoppa‐Lyonnet, Dominique , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tung, Nadine , Asperen, Christi J. van , Yannoukakos, Drakoulis , Collaborators, GEMO Study, HEBON, EMBRACE, Rebbeck, Timothy R. , Feliubadaló, Lidia , Gómez-García, Encarna B , Terry, Mary Beth , Kwong, Ava

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 3, 2018 | Volume: 111 | Issue: 4 | Pages: 350-364

10.1093/jnci/djy132 | PMID 30312457 Get It

Yoga as a survivorship tool in cancer patients and caregivers.
Tan, Winston , Ailawadhi, Meghna

Mayo Clinic

Journal of Clinical Oncology | May 29, 2018 | Volume: 36 | Issue: 7_suppl | Pages: 90-90

10.1200/jco.2018.36.7_suppl.90 Get It

90 Background: Preliminary data suggest that yoga is one of the most popular complementary and alternative therapies and most likely to improve quality of life. In spite of the methodologic limits,studies suggest an improvement in a range of symptoms of patients with cancer among those who did yoga. The absence of side effects and the excellent cost-benefit ratio make it a very interesting symptom management tool. Methods: We advertised to our cancer patients the availability of a free yoga class twice a week. (August 2016-present). This was run by one trained instructor. All patients with different cancers were allowed to participate including caregivers. A post session survey was done at one time point to evaluate the benefits of the class. Results: Usually between 8-15 individuals attend the class. In one session a written survey was conducted, 13 patients/caregiver agreed to fill up the survey. 9 were patients (breast , sarcoma, lymphoma, brain tumor melanoma and spine tumor) and 5 were caregivers.4 never had any prior yoga class before, the reasons for attending the class included stress relief, improve balance, help pain, support spouse, suggestion by MD and exercise. Among those who answered the question 7 were new to yoga 0-3 month, they mainly did restorative and gentle yoga. The perceived benefits among attendees included being more relaxed, calm down, peaceful, increase strength, more mindful and better health. 8/13 perceived that it did improve quality of life very much, 3/13 quite a bit 1 a little. All were very satisfied with the yoga sessions. Conclusions: In an undifferentiated group of cancer patients, yoga classes participants have positive perceived benefits in majority of the individuals who did restorative/gentle yoga. This led to symptom control and also had significant participant satisfaction.
Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma
Niazi, Shehzad K. , Frank, Ryan D. , Sharma, Mayank , Ames, Steve, Rummans, Teresa A. , Spaulding, Aaron , Sher, Taimur , Ailawadhi, Meghna, Bhatia, Kirtipal, Ahmed, Salman , Tan, Winston , Chanan‐Khan, Asher , Niazi, Shehzad, Rummans, Teresa, Spaulding, Aaron , Roy, Vivek , Ailawadhi, Sikander

Mayo Clinic

Blood Advances | May 18, 2018 | Volume: 2 | Issue: 10 | Pages: 1120-1128

10.1182/bloodadvances.2018016717 | PMID 29776984 Get It

Key PointsCoexisting psychiatric comorbidities are associated with greater increased health care utilization and cost of care in patients with MM. Clinical complications of MM are seen more frequently in patients with coexisting psychiatric conditions.
Right Ventricular Dysfunction and Long-Term Risk of Sudden Cardiac Death in Patients With and Without Severe Left Ventricular Dysfunction
Naksuk, Niyada , Tan, Nicholas Y. , Padmanabhan, Deepak , Kancharla, Krishna , Makkar, Nayani , Yogeswaran, Vidhushei , Gaba, Prakriti , Kaginele, Pranita , Riley, David C., Sugrue, Alan , Rosenbaum, Andrew , El‐Harasis, Majd , Asirvatham, Samuel J. , Asirvatham, Samuel J , Kapa, Suraj , McLeod, Christopher J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 16, 2018 | Volume: 11 | Issue: 6 | Pages: No page available

10.1161/circep.117.006091 | PMID 29769224 Get It

Background: Right ventricular systolic dysfunction (RVD) often coexists with various cardiopulmonary diseases. However, the association between RVD and risk of sudden cardiac death (SCD) has not been well studied. This study examined the risk of SCD associated with RVD in patients with heterogeneous underlying cardiac diseases. Methods: The Mayo Clinic cardiac care unit database included 5463 consecutive patients with complete echocardiographic evaluation to assess right ventricular systolic function and RVD severity. Prospective surveillance follow-up was obtained for all patients. SCD was adjudicated when a malignant ventricular arrhythmia was documented as the primary rhythm leading to death. RESULTS: The prevalence of mild RVD and moderate-severe RVD was 14.9% and 17.1%, respectively. Patients with RVD were more likely to have a history of congestive heart failure, cardiac arrest, pulmonary disease, and lower baseline left ventricular ejection fraction compared with those with normal right ventricular systolic function. During a median follow-up of 14 months, the incidence of SCD was highest in patients with moderate-severe RVD (7.4% versus 4.4% in mild RVD versus 1.6% in normal right ventricular function; P <0.001). After adjustment for baseline characteristics, mild RVD (adjusted hazard ratio, 1.57; P =0.046) and moderate-severe RVD (adjusted hazard ratio, 1.91; P =0.006) were independently associated with an increased risk of SCD. Moderate-severe RVD remained an independent predictor of SCD for patients with left ventricular ejection fraction >35% without or with preexisting implantable cardioverter-defibrillator (adjusted hazard ratio, 4.12; P =0.003 and adjusted hazard ratio, 5.04; P <0.001, respectively). Conclusions: Presence of RVD in patients with a history of preexisting cardiac disease is an independent predictor of SCD irrespective of left ventricular ejection fraction.
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Sciver, Robert E. Van , Lee, Michael , Lafever, Alex, Svyatova, Elizaveta , Kanda, Kevin, Collier, Amber L. , Reesema, LL Siewertsz van, Tang-Tan, Angela M., Zheleva, Vasilena, Bwayi, Monicah, Bian, Minglei, Schmidt, Rebecca L., Matrisian, Lynn M. , Petersen, Gloria M. , Van Sciver, Robert E , Matrisian, Lynn M , Lee, Caroline Guat Lay , Tang, Amy

Mayo Clinic

Cancers | May 15, 2018 | Volume: 10 | Issue: 5 | Pages: 142

10.3390/cancers10050142 | PMID 29757973 Get It

Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targeting an upstream component of the RAS signaling pathway (i.e., EGFR/HER2) and/or the midstream effector kinases (i.e., RAF/MEK/ERK/PI3K/mTOR), we propose an alternative strategy to control oncogenic K-RAS signal by targeting its most downstream signaling module, Seven-In-Absentia Homolog (SIAH). SIAH E3 ligase controls the signal output of oncogenic K-RAS hyperactivation that drives unchecked cell proliferation, uncontrolled tumor growth, and rapid cancer cell dissemination in human pancreatic cancer. Therefore, SIAH is an ideal therapeutic target as it is an extraordinarily conserved downstream signaling gatekeeper indispensable for proper RAS signaling. Guided by molecular insights and core principles obtained from developmental and evolutionary biology, we propose an anti-SIAH-centered anti-K-RAS strategy as a logical and alternative anticancer strategy to dampen uncontrolled K-RAS hyperactivation and halt tumor growth and metastasis in pancreatic cancer. The clinical utility of developing SIAH as both a tumor-specific and therapy-responsive biomarker, as well as a viable anti-K-RAS drug target, is logically simple and conceptually innovative. SIAH clearly constitutes a major tumor vulnerability and K-RAS signaling bottleneck in pancreatic ductal adenocarcinoma (PDAC). Given the high degree of evolutionary conservation in the K-RAS/SIAH signaling pathway, an anti-SIAH-based anti-PDAC therapy will synergize with covalent K-RAS inhibitors and direct K-RAS targeted initiatives to control and eradicate pancreatic cancer in the future.
Closing The Brief Case: A “Fresh” Pair of Contact Lenses
Tan, Eugene M. , Starr, Matthew R. , Henry, Michael , Pritt, Bobbi S. , Henry, Michael R, Tan, E M , Pritt, Bobbi S , Starr, Matthew R

Mayo Clinic

Journal of Clinical Microbiology | April 24, 2018 | Volume: 56 | Issue: 5 | Pages: No page available

10.1128/jcm.00791-17 | PMID 29695543 Get It

The Brief Case: A “Fresh” Pair of Contact Lenses
Tan, Eugene M. , Starr, Matthew R. , Henry, Michael , Pritt, Bobbi S. , Henry, Michael R, Tan, E M , Pritt, Bobbi S , Starr, Matthew R

Mayo Clinic

Journal of Clinical Microbiology | April 24, 2018 | Volume: 56 | Issue: 5 | Pages: No page available

10.1128/jcm.00790-17 | PMID 29695542 Get It

Concurrent Sweet’s syndrome and myopericarditis following mesalamine therapy
Shabtaie, Samuel A. , Tan, Nicholas Y. , Parikh, Riddhi S. , Papadakis, Konstantinos A.

Mayo Clinic

BMJ Case Reports | March 24, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2017-223851

10.1136/bcr-2017-223851 | PMID 29574433 Get It

Mesalamine, or 5-aminosalicylic acid, is a frequently used medication for the treatment of inflammatory bowel disease (IBD). We report the case of a 40-year-old woman recently diagnosed with IBD and started on mesalamine, who presented with new onset tender skin lesions 3 days following medication administration. One day following the onset of skin lesions, the patient developed acute chest pain, shortness of breath, ECG changes, troponemia, C-reactive protein elevation and pericardial enhancement on cardiac MRI consistent with myopericarditis. Subsequent skin biopsy confirmed the diagnosis of Sweet’s syndrome. On cessation of the drug, both the skin lesions and the cardiac symptoms resolved in combination with anti-inflammatory therapy. While mesalamine has been previously associated with myocarditis and pericarditis, to our knowledge this is the first case of coexisting Sweet’s syndrome with myopericarditis in the context of mesalamine therapy.